Correlation between LAT1 expression level and risk of postoperative relapse in patients with non-muscle invasive bladder cancer

Chen Jiangchuan; Zhang Xuan; Luo Huaming; Zhang Jiamo

doi:10.13406/j.cnki.cyxb.003305

您当前的位置：

首页 >

文章列表页 >

Correlation between LAT1 expression level and risk of postoperative relapse in patients with non-muscle invasive bladder cancer

Carcinoma of bladder | 更新时间：2025-10-21

- Correlation between LAT1 expression level and risk of postoperative relapse in patients with non-muscle invasive bladder cancer
- Journal of Chongqing Medical University Vol. 48, Issue 8, Pages: 885-888(2023)
- 作者机构：
  
  重庆医科大学附属永川医院泌尿外科，重庆 402160
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003305
  CLC： R694
- Received：15 April 2023，
  
  Revised：2023-06-22，
  
  Accepted：30 June 2023，
  
  Published：28 August 2023
- 稿件说明：
移动端阅览
陈江川,张翾,罗华铭,等.LAT1表达水平与非肌层浸润性膀胱癌患者术后复发风险的相关性研究[J].重庆医科大学学报,2023,48(8):885-888.

Chen Jiangchuan,Zhang Xuan,Luo Huaming,et al.Correlation between LAT1 expression level and risk of postoperative relapse in patients with non-muscle invasive bladder cancer[J].Journal of Chongqing Medical University,2023,48(8):885-888.
陈江川,张翾,罗华铭,等.LAT1表达水平与非肌层浸润性膀胱癌患者术后复发风险的相关性研究[J].重庆医科大学学报,2023,48(8):885-888. DOI： 10.13406/j.cnki.cyxb.003305.

Chen Jiangchuan,Zhang Xuan,Luo Huaming,et al.Correlation between LAT1 expression level and risk of postoperative relapse in patients with non-muscle invasive bladder cancer[J].Journal of Chongqing Medical University,2023,48(8):885-888. DOI： 10.13406/j.cnki.cyxb.003305.

摘要

目的

探讨L型氨基酸转运蛋白1（L-type amino acid transporter 1，LAT）表达水平与非肌层浸润性膀胱癌患者术后复发风险的相关性。

方法

选取2021年2月至2022年2月于重庆医科大学附属永川医院接受手术治疗的非肌层浸润性膀胱癌患者108例作为研究对象，采用反转录酶聚合酶链反应测定膀胱癌组织（取自肿瘤所在部位区域）和癌旁组织（取自邻近正常区域组织）LAT1表达含量，对比膀胱癌组织和癌旁组织LAT1表达水平。同时根据膀胱癌组织LAT1表达含量的二分位数将所有患者分为高表达组和低表达组，对比2组临床病理参数。随访观察12个月观察2组术后复发情况，采用Kaplan-Meier曲线分析对比2组术后复发风险，使用多变量Cox比例风险回归模型确定术后复发的影响因素。

结果

膀胱癌组织LAT1表达水平（1.80±0.35）较配对的癌旁组织LAT1表达水平（1.05±0.17）高（

0.05）；LAT1高表达组吸烟史、临床分期T

占比较LAT1低表达组高（

0.05）；108例膀胱肿瘤患者术后的平均随访时间为（10.84±1.94）个月，其中33例复发，复发率为30.56%。Kaplan-Meier曲线显示，LAT1高表达组患者总体复发率较LAT1低表达组高（log-rank

²=4.382，

=0.036）；多因素Cox回归分析显示，吸烟史（

=6.539，95%CI=2.439~17.531）、临床分期为T

期（

=3.658，95%CI=1.808~7.398）、LAT1高表达（

=3.425，95%CI=1.631~7.191）为非肌层浸润性膀胱癌患者术后复发的危险因素（

0.05）。

结论

LAT1在膀胱癌组织中表达水平高，高LAT1表达水平可能与膀胱癌患者术后复发风险增加有关。

Abstract

Objective

To explore the correlation between the expression level of L-type amino acid transporter 1（LAT1） and the risk of postoperative relapse in patients with non-muscle-invasive bladder cancer（NMIBC）.

Methods

A total of 108 patients with NMIBC who received surgical treatment in Yongchuan Hospital Affiliated to Chongqing Medical University from February 2021 to February 2022 were selected as subjects. LAT1 expression levels in the bladder cancer tissue （from the sites where tumor was identified） and paracancerous tissue（from adjacent normal areas） were measured by reverse transcriptase polymerase chain reaction，and the expression levels of LAT1 in the two types of tissue were compared. Meanwhile，all patients were divided into high expression group and low expression group according to the second quantile of LAT1 expression in the bladder cancer tissue，and the clinicopathological parameters of the two groups were compared. The two groups were observed and followed up for 12 months for postoperative relapse. The Kaplan-Meier curve was used to analyze and compare the risk of postoperative relapse between the two groups. The multivariate

Cox

proportional hazards regression model was used to determine the influencing factors for postoperative relapse.

Results

The LAT1 expression level in the bladder cancer tissue（1.80±0.35） was significantly higher than that in the paired paracancerous tissue（1.05±0.17）（

0.05）. The proportion of patients with a smoking history and clinical stage T

was significantly higher in the high LAT1 expression group than in the low LAT1 expression group（

0.05）. The mean follow-up time of 108 patients with bladder tumor was （10.84±1.94） months. Among these patients，33 had a relapse，with a rel

apse rate of 30.56%. The Kaplan-Meier curve showed that the overall relapse rate was significantly higher in patients with high LAT1 expression than in those with low LAT1 expression（log rank

χ²

=4.382，

=0.036）；the multivariate

Cox

regression analysis showed that smoking history [hazard ratio（

）=6.539，95%CI=2.439-17.531

]

，clinical stage T

（

=3.658，95%CI=1.808-7.398），and high LAT1 expression（

=3.425，95%CI=1.631-7.191） were risk factors for postoperative relapse of patients with NMIBC

0.05）.

Conclusion

The LAT1 expression level is high in the bladder cancer tissue，and high LAT1 expression levels may be correlated with an increased risk of postoperative relapse in patients with bladder cancer.

关键词

Keywords

references

Dobruch J ， Oszczudłowski M . Bladder cancer：current challenges and future directions [J ] . Medicina ， 2021 ， 57 （ 8 ）： 749 - 759 .

Ng K ， Stenzl A ， Sharma A ， et al . Urinary biomarkers in bladder cancer：a review of the current landscape and future directions [J ] . Urol Oncol ， 2021 ， 39 （ 1 ）： 41 - 51 .

Stepka P ， Vsiansky V ， Raudenska M ， et al . Metabolic and amino acid alterations of the tumor microenvironment [J ] . Curr Med Chem ， 2021 ， 28 （ 7 ）： 1270 - 1289 .

Häfliger P ， Charles RP . The L-type amino acid transporter LAT1-an emerging target in cancer [J ] . Int J Mol Sci ， 2019 ， 20 （ 10 ）： 2428 - 2442 .

Kurozumi S ， Kaira K ， Matsumoto H ， et al . Association of L-type amino acid transporter 1（LAT1） with the immune system and prognosis in invasive breast cancer [J ] . Sci Rep ， 2022 ， 12 （ 1 ）： 2742 - 2757 .

Rajasinghe LD ， Hutchings M ， Gupta SV . Delta-tocotrienol modulates glutamine dependence by inhibiting ASCT2 and LAT1 transporters in non-small cell lung cancer（NSCLC） cells：a metabolomic approach [J ] . Metabolites ， 2019 ， 9 （ 3 ）： 50 - 71 .

中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南（2018年标准版） [J ] . 现代泌尿外科杂志， 2019 ， 24 （ 7 ）： 516 - 542 .

Evidence-based clinical practice guidelines for the treatment and monitoring of non-muscular invasive bladder cancer in China （ 2018 standard edition） [J ] . J Mod Urol ， 2019 ， 24 （ 7 ）： 516 - 542 .

Fattahi MJ ， Haghshenas MR ， Ghaderi A . Immunometabolism in the bladder cancer microenvironment [J ] . Endocr Metab Immune Disord Drug Targets ， 2022 ， 22 （ 12 ）： 1201 - 1216 .

Sivanand S ， Vander Heiden MG . Emerging roles for branched-chain amino acid metabolism in cancer [J ] . Cancer Cell ， 2020 ， 37 （ 2 ）： 147 - 156 .

Martinez RS ， Salji MJ ， Rushworth L ， et al . SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer [J ] . Cancer Res ， 2021 ， 81 （ 13 ）： 3664 - 3678 .

Park Y ， Han Y ， Kim D ， et al . Impact of exogenous treatment with histidine on hepatocellular carcinoma cells [J ] . Cancers ， 2022 ， 14 （ 5 ）： 1205 .

Sato K ， Miyamoto M ， Takano M ， et al . Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma [J ] . Virchows Arch ， 2019 ， 474 （ 6 ）： 701 - 710 .

Lu JJ ， Li P ， Yang Y ， et al . Prognostic value of LAT-1 status in solid cancer：a systematic review and Meta-analysis [J ] . PLoS One ， 2020 ， 15 （ 5 ）： e0233629 .

Maimaiti M ， Sakamoto S ， Yamada Y ， et al . Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma [J ] . Sci Rep ， 2020 ， 10 （ 1 ）： 1292 - 1306 .

Park J ， Shin DW ， Kim TH ， et al . Development and validation of the Korean version of the European organization for research and treatment of cancer quality of life questionnaire for patients with non-muscle invasive bladder cancer：EORTC QLQ-NMIBC24 [J ] . Cancer Res Treat ， 2018 ， 50 （ 1 ）： 40 - 49 .

Mitin T ， Choudhury A . The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer [J ] . World J Urol ， 2019 ， 37 （ 9 ）： 1767 - 1772 .

Scholtes MP ， Alberts AR ， Iflé IG ， et al . Biomarker-oriented therapy in bladder and renal cancer [J ] . Int J Mol Sci ， 2021 ， 22 （ 6 ）： 2832 - 2850 .

Lindskrog SV ， Prip F ， Lamy P ， et al . An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer [J ] . Nat Commun ， 2021 ， 12 （ 1 ）： 2301 - 2319 .

Sawazaki H ， Arai Y ， Ito Y ， et al . Expression of L-type amino acid transporter 1 is a predictive biomarker of intravesical recurrence in patients with non-muscle invasive bladder cancer [J ] . Res Rep Urol ， 2021 ， 13 ： 603 - 611 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Current status of depression and its correlation with psychological resilience in patients with acute aortic dissection

Assessment of tumor-associated fibroblast as a biomarker for predicting recurrence of non-muscle invasive bladder cancer

Correlation between serum sterol regulatory element binding protein-2 and acute cerebral infarction

Study on the correlation between subtypes of cerebral small vessel disease, extracranial carotid arteriosclerosis and vascular cognitive impairment

Related Author

Luo Yuan

Guo Yongzheng

Kong Lingwen

Zhao Boying

Wang Ying

He Weiyang

Gou Xin

Feng Zhenwei

Related Institution

Chongqing Emergency Medical Center，Central Hospital Affiliated to Chongqing University， Department of Thoracic and Cardiac Surgery，Chongqing Fourth People’s Hospital

Department of Cardiology，The First Affiliated Hospital of Chongqing Medical University

Department of Urinary Surgery，The First Affiliated Hospital of Chongqing Medical University

Department of Neurology，The First Affiliated Hospital of Chongqing Medical University

Department of Neurology, Tinglin Hospital of Jinshan District Shanghai

⁰